Analysts predict upwards adjustment of Novo Nordisk
Share analysts continue to see favorable tailwinds for Novo Nordisk, perhaps leading to yet another upwards adjustment of the pharmaceutical company, Danish business daily Børsen reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Berenberg predicts an obesity market of USD 85bn by 2030
For subscribers
UBS skeptical of Novo Nordisk's sky-high market valuation
For subscribers